EGFR and prostate cancer: In another case, where the effect of cetuximab, an anti-EGFR drug monoclonal antibody, on the growth of androgen-independent prostate cancer cells was evaluated, the drug-induced reduction of the Y845 phosphorylation did not necessarily correlate with the reduction in the growth potential of the cells [96], demonstrating that, under certain conditions, the Y845 phosphorylation of EGFR is dispensable for the EGFR-dependent cancer cell malignancy.